Table 4.

Effect of each parameter on OS according to baseline values and to the variation between T1 value (after 1 month of therapy) and T0 value (baseline value). This difference has been indicated as delta value (Δ)

Parameter			Univariate				Two-variable				Multivariablea
Variable	Timepoint	Value	p	HR	Lower HR	Upper HR	p	HR	Lower HR	Upper HR	p	HR	Lower HR	Upper HR
Platelets	Basal	+ 10,000					0.041	1.020	1.001	1.039	–	–	–	–
	Δ	Ref ≤ 25,000					0.022	1.512	1.063	2.151	–	–	–	–
White blood cell count	Basal	+ 100					< 0.001	1.009	1.005	1.013	–	–	–	–
	Δ	Ref ≤ 1920					< 0.001	3.246	2.171	4.854	< 0.001	2.918	1.882	4.526
Neutrophils	Basal	+ 100					< 0.001	1.014	1.010	1.018	< 0.001	1.011	1.005	1.016
	Δ	Ref ≤ 310					< 0.001	1.880	1.330	2.659	–	–	–	–
Lymphocytes	Basal	+ 100					0.045	0.977	0.955	0.999	–	–	–	–
	Δ	Ref ≥ -300					< 0.001	2.319	1.578	3.409	0.038	1.627	1.028	2.576
NL ratio	Basal	+ 1					< 0.001	1.279	1.169	1.400	–	–	–	–
	Δ	Ref ≤ 0.86					< 0.001	2.908	2.012	4.202	–	–	–	–
PL ratio	Basal	+ 1					0.006	1.003	1.001	1.005	0.022	1.003	1.000	1.005
	Δ	Ref ≤ 22.85					< 0.001	2.019	1.429	2.853	0.140	1.378	0.901	2.109
Age	Basal	+ 1	0.255	1.008	0.994	1.021					–	–	–	–
Sex	Basal	Ref F	0.282	0.829	0.589	1.166					–	–	–	–
Number of metastatic sites	Basal	Ref ≥ 3	0.089	0.746	0.532	1.046					–	–	–	–
LDH	Basal	Ref elevated	< 0.001	0.395	0.276	0.564					< 0.001	0.499	0.344	0.724

Statistically significant values in bold

At the Δ timepoint the variables have been dichotomized and the “value” represents the reference category

HR (hazard ratio) values are expressed in terms of risk of mortality

^aAfter stepwise selection